Cardiovascular Toxicities of Ibrutinib: A Pharmacovigilance Study Based on the United States Food and Drug Administration Adverse Event Reporting System Database
Background: Although ibrutinib has been widely used to treat haematological malignancies, many studies have reported associated cardiovascular events. These studies were primarily animal experiments and clinical trials. For more rational clinical drug use, a study based on post-marketing data is nec...
Saved in:
Main Authors: | Yi Zheng (Author), Xiaojing Guo (Author), Chenxin Chen (Author), Lijie Chi (Author), Zhijian Guo (Author), Jizhou Liang (Author), Lianhui Wei (Author), Xiao Chen (Author), Xiaofei Ye (Author), Jia He (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2023-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Cardiotoxicity Induced by Immune Checkpoint Inhibitors: A Pharmacovigilance Study From 2014 to 2019 Based on FAERS
by: Chenxin Chen, et al.
Published: (2021) -
Safety Profile of Ibrutinib: An Analysis of the WHO Pharmacovigilance Database
by: Marion Allouchery, et al.
Published: (2021) -
Pharmacovigilance of esketamine nasal spray: an analysis of the FDA adverse event reporting system database
by: Ruixue Liu, et al.
Published: (2024) -
Pericardial Toxicities Associated With Immune Checkpoint Inhibitors: A Pharmacovigilance Analysis of the FDA Adverse Event Reporting System (FAERS) Database
by: Zhuo Ma, et al.
Published: (2021) -
Psychiatric disorders associated with fluoroquinolones: a pharmacovigilance analysis of the FDA adverse event reporting system database
by: Wen-Long Xie, et al.
Published: (2024)